TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the F...
This three-year collaboration aims to validate genetic drug targets and progress therapeutic molecules into clinical development. The joint resea...
Safety data encouraging with no graft-versus-host-disease and no neurotoxicity Updated data highlighted in podium presentation at the 17th International...
SciMed offers life science products and services, including ultra-low temperature freezers and CO2 incubators, in Southeast Asia, India, and Oceania. Since...
Under the terms of the agreement, the two companies aim to develop multiple targeted protein degraders by combining Cullgen's proprietary uSMITE™ tar...
Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetyl...
"We are very pleased about the cooperation with Novaliq, a pioneer for groundbreaking non-aqueous eye drop technology. With regard to the unique properties...
-Klick Health announced it has opened an Asia-Pacific hub in Singapore, headed up by veteran agency executives Mitchell Tan, Dr. Shraddha Tawate, Dr....
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial1 is being led by Lanhzou Biotechnique Development wi...
Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, is delighted to an...
Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product bios...
BetaLife wins top prize with its potential to provide regenerative medicines to patients with severe diabetes in Southeast Asia. Cytiva’s BioChall...
Over the past several years, management has initiated discussions with potential strategic collaborators to provide the resources to advance PRP into clini...
HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated fro...
© 2024 Biopharma Boardroom. All Rights Reserved.
